<DOC>
	<DOC>NCT00592969</DOC>
	<brief_summary>This trial is conducted in South America. The aim of this trial is to evaluate the efficacy of metformin plus biphasic insulin aspart or insulin NPH on blood glucose control in subjects with type 2 diabetes.</brief_summary>
	<brief_title>Efficacy and Safety of Metformin Plus Biphasic Insulin Aspart 30 in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<criteria>Type 2 diabetes Currently treated with insulin NPH or are insulinnaive Body mass index (BMI) below 35.0 kg/m2 HbA1c between 7.511.0% Participation in any other clinical trial involving investigational products within the last 3 months History of drug or alcohol dependence Known impaired hepatic function Known or suspected allergy to human insulin NPH, insulin aspart or any component of the composition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>